BACKGROUND: Reduced bone mineral density (BMD) is a significant sequelae in children receiving chemotherapy for acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). Reduced BMD is associated with an increased risk for fractures. Pamidronate, a second-generation bisphosphonate, has been used to treat osteoporosis in children. This study evaluated the safety and efficacy of pamidronate in children with low BMD during and after chemotherapy for ALL and NHL. METHODS: Between April 2007 and October 2011, 24 children with ALL and NHL were treated with pamidronate. The indication was a decreased BMD Z-score less than -2.0 or bone pain with a BMD Z-score less than 0. Pamidronate was infused at 1 mg/kg/day for 3 days at 1-4 month intervals (pamidronate group, cases). The BMD Z-scores of the cases were compared with those of 10 untreated patients (control group). Lumbar spine BMDs were measured every 6 cycles using dual energy X-ray absorptiometry and Z-scores were calculated. Bone turnover parameters (25-hydroxyvitamin D, alkaline phosphatase, parathyroid hormone, osteocalcin, and type I collagen c-terminal telopeptide) were analyzed. RESULTS: The median cycle of pamidronate treatment was 12. Increases in BMD Z-scores were significantly higher in the pamidronate group than in the control group (P<0.001). BMD (mg/cm(2)) increased in all pamidronate-treated cases. Twenty patients who complained of bone pain reported pain relief after therapy. The treatment was well tolerated. CONCLUSION: Pamidronate appears to be safe and effective for the treatment of children with low BMD during and after chemotherapy for ALL and NHL.
BACKGROUND: Reduced bone mineral density (BMD) is a significant sequelae in children receiving chemotherapy for acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). Reduced BMD is associated with an increased risk for fractures. Pamidronate, a second-generation bisphosphonate, has been used to treat osteoporosis in children. This study evaluated the safety and efficacy of pamidronate in children with low BMD during and after chemotherapy for ALL and NHL. METHODS: Between April 2007 and October 2011, 24 children with ALL and NHL were treated with pamidronate. The indication was a decreased BMD Z-score less than -2.0 or bone pain with a BMD Z-score less than 0. Pamidronate was infused at 1 mg/kg/day for 3 days at 1-4 month intervals (pamidronate group, cases). The BMD Z-scores of the cases were compared with those of 10 untreated patients (control group). Lumbar spine BMDs were measured every 6 cycles using dual energy X-ray absorptiometry and Z-scores were calculated. Bone turnover parameters (25-hydroxyvitamin D, alkaline phosphatase, parathyroid hormone, osteocalcin, and type I collagen c-terminal telopeptide) were analyzed. RESULTS: The median cycle of pamidronate treatment was 12. Increases in BMD Z-scores were significantly higher in the pamidronate group than in the control group (P<0.001). BMD (mg/cm(2)) increased in all pamidronate-treated cases. Twenty patients who complained of bone pain reported pain relief after therapy. The treatment was well tolerated. CONCLUSION:Pamidronate appears to be safe and effective for the treatment of children with low BMD during and after chemotherapy for ALL and NHL.
Entities:
Keywords:
ALL; Bisphosphonate; Bone mineral density; Corticosteroids; NHL; Pamidronate
Authors: Wolfgang Högler; Götz Wehl; Tjeerd van Staa; Bernhard Meister; Andreas Klein-Franke; Gabriele Kropshofer Journal: Pediatr Blood Cancer Date: 2007-01 Impact factor: 3.167
Authors: Paul A Meyers; John H Healey; Alexander J Chou; Leonard H Wexler; Pamela R Merola; Carol D Morris; Michael P Laquaglia; Michael G Kellick; Sara J Abramson; Richard Gorlick Journal: Cancer Date: 2010-11-08 Impact factor: 6.860
Authors: Rishi S Kotecha; Neil Powers; Senq-J Lee; Kevin J Murray; Tina Carter; Catherine Cole Journal: Pediatr Blood Cancer Date: 2010-07-01 Impact factor: 3.167
Authors: Karen Wasilewski-Masker; Sue C Kaste; Melissa M Hudson; Natia Esiashvili; Leonard A Mattano; Lillian R Meacham Journal: Pediatrics Date: 2008-03 Impact factor: 7.124
Authors: Jenneke E van Atteveld; Saskia M F Pluijm; Kirsten K Ness; Melissa M Hudson; Wassim Chemaitilly; Sue C Kaste; Leslie L Robison; Sebastian J C M M Neggers; Yutaka Yasui; Marry M van den Heuvel-Eibrink; Carmen L Wilson Journal: J Clin Oncol Date: 2019-05-31 Impact factor: 50.717